Compare
| A | B | A − B | |
|---|---|---|---|
| Patients | 49 | 218 | -169 |
| Mean treatment day | 156 | 156 | 0 |
| Strong responders | 0% | 100% | -100% |
| Discontinuation risk ≥ 70% | 0% | 0% | 0% |
| At risk | 0% | 0% | 0% |
| Tolerance deteriorating | 33% | 27% | +6% |
| GI unstable | 0% | 0% | 0% |
| Response today | 41 | 81 | -40 |
| GI burden today | 18 | 17 | +1 |
| Toxicity today | 17 | 15 | +2 |
| Adherence | 84% | 92% | -8% |
| Quality of life | 56 | 77 | -21 |
| Segment | A | B | A − B |
|---|---|---|---|
| FUT2 non-secretor | 80% | 23% | +57 pp |
| IL6 high-expression variant | 55% | 20% | +35 pp |
| Poor metabolizer | 37% | 17% | +20 pp |
| Low butyrate capacity | 65% | 0% | +65 pp |
| Low microbial diversity | 84% | 11% | +73 pp |
| Baseline state S14 | 6% | 6% | 0 pp |
| Cluster EC-03 (high response / high intolerance) | 0% | 0% | 0 pp |
| Adherence < 60% | 0% | 0% | 0 pp |
EC-01 · Delayed loss of response: 49 patients, mean day 156. 33% have deteriorating tolerance, 0% unstable GI, 0% carry ≥60% discontinuation risk; mean GI 18, adherence 84%. Dominant clusters: EC-01 100%.
Shared biology: Low microbial diversity 84%, FUT2 non-secretor 80%, Low butyrate capacity 65%, IL6 high-expression variant 55%, Poor metabolizer 37%. Dietary detractors: ultraProcessed in 88%, fat in 82%, simpleCarbs in 80%.
What worked: AD-05 improved 20% of 5; what did not: BR-03 improved only 14% of 7. By biology: BR-03 works best in FUT2 non-secretor (17%) and worst in IL6 high-expression variant (0%).
No learned rules apply yet; run learning after the first campaign results.
minResponseProbability 0.65: 218 patients, mean day 156. 27% have deteriorating tolerance, 0% unstable GI, 0% carry ≥60% discontinuation risk; mean GI 17, adherence 92%. Dominant clusters: SR 83%, EC-02 11%, MR 6%.
Shared biology: no dominant biology. Dietary detractors: ultraProcessed in 30%, alcohol in 29%, simpleCarbs in 11%.
What worked: SC-12 improved 25% of 4.
No learned rules apply yet; run learning after the first campaign results.